Deep Learning Assisted Diagnosis of Musculoskeletal Tumors Based on Contrast-Enhanced Magnetic Resonance Imaging

Advancing musculoskeletal tumor diagnosis: Automated segmentation and predictive classification using deep learning and radiomics

OBJECTIVES

Musculoskeletal (MSK) tumors, given their high mortality rate and heterogeneity, necessitate precise examination and diagnosis to guide clinical treatment effectively. Magnetic resonance imaging (MRI) is pivotal in detecting MSK tumors, as it offers exceptional image contrast between bone and soft tissue. This study aims to enhance the speed of detection and the diagnostic accuracy of MSK tumors through automated segmentation and grading utilizing MRI.

MATERIALS AND METHODS

The research included 170 patients (mean age, 58 years ±12 (standard deviation), 84 men) with MSK lesions, who underwent MRI scans from April 2021 to May 2023. We proposed a deep learning (DL) segmentation model MSAPN based on multi-scale attention and pixel-level reconstruction, and compared it with existing algorithms. Using MSAPN-segmented lesions to extract their radiomic features for the benign and malignant classification of tumors.

RESULTS

Compared to the most advanced segmentation algorithms, MSAPN demonstrates better performance. The Dice similarity coefficients (DSC) are 0.871 and 0.815 in the testing set and independent validation set, respectively. The radiomics model for classifying benign and malignant lesions achieves an accuracy of 0.890. Moreover, there is no statistically significant difference between the radiomics model based on manual segmentation and MSAPN segmentation.

CONCLUSION

This research contributes to the advancement of MSK tumor diagnosis through automated segmentation and predictive classification. The integration of DL algorithms and radiomics shows promising results, and the visualization analysis of feature maps enhances clinical interpretability.

Diagnostic Performance of Artificial Intelligence in Detection of Primary Malignant Bone Tumors: a Meta-Analysis

We aim to conduct a meta-analysis on studies that evaluated the diagnostic performance of artificial intelligence (AI) algorithms in the detection of primary bone tumors, distinguishing them from other bone lesions, and comparing them with clinician assessment. A systematic search was conducted using a combination of keywords related to bone tumors and AI. After extracting contingency tables from all included studies, we performed a meta-analysis using random-effects model to determine the pooled sensitivity and specificity, accompanied by their respective 95% confidence intervals (CI). Quality assessment was evaluated using a modified version of Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) and Prediction Model Study Risk of Bias Assessment Tool (PROBAST). The pooled sensitivities for AI algorithms and clinicians on internal validation test sets for detecting bone neoplasms were 84% (95% CI: 79.88) and 76% (95% CI: 64.85), and pooled specificities were 86% (95% CI: 81.90) and 64% (95% CI: 55.72), respectively. At external validation, the pooled sensitivity and specificity for AI algorithms were 84% (95% CI: 75.90) and 91% (95% CI: 83.96), respectively. The same numbers for clinicians were 85% (95% CI: 73.92) and 94% (95% CI: 89.97), respectively. The sensitivity and specificity for clinicians with AI assistance were 95% (95% CI: 86.98) and 57% (95% CI: 48.66). Caution is needed when interpreting findings due to potential limitations. Further research is needed to bridge this gap in scientific understanding and promote effective implementation for medical practice advancement.

The diagnostic value of machine learning for the classification of malignant bone tumor: a systematic evaluation and meta-analysis

Background

Malignant bone tumors are a type of cancer with varying malignancy and prognosis. Accurate diagnosis and classification are crucial for treatment and prognosis assessment. Machine learning has been introduced for early differential diagnosis of malignant bone tumors, but its performance is controversial. This systematic review and meta-analysis aims to explore the diagnostic value of machine learning for malignant bone tumors.

Methods

PubMed, Embase, Cochrane Library, and Web of Science were searched for literature on machine learning in the differential diagnosis of malignant bone tumors up to October 31, 2022. The risk of bias assessment was conducted using QUADAS-2. A bivariate mixed-effects model was used for meta-analysis, with subgroup analyses by machine learning methods and modeling approaches.

Results

The inclusion comprised 31 publications with 382,371 patients, including 141,315 with malignant bone tumors. Meta-analysis results showed machine learning sensitivity and specificity of 0.87 [95% CI: 0.81,0.91] and 0.91 [95% CI: 0.86,0.94] in the training set, and 0.83 [95% CI: 0.74,0.89] and 0.87 [95% CI: 0.79,0.92] in the validation set. Subgroup analysis revealed MRI-based radiomics was the most common approach, with sensitivity and specificity of 0.85 [95% CI: 0.74,0.91] and 0.87 [95% CI: 0.81,0.91] in the training set, and 0.79 [95% CI: 0.70,0.86] and 0.79 [95% CI: 0.70,0.86] in the validation set. Convolutional neural networks were the most common model type, with sensitivity and specificity of 0.86 [95% CI: 0.72,0.94] and 0.92 [95% CI: 0.82,0.97] in the training set, and 0.87 [95% CI: 0.51,0.98] and 0.87 [95% CI: 0.69,0.96] in the validation set.

Conclusion

Machine learning is mainly applied in radiomics for diagnosing malignant bone tumors, showing desirable diagnostic performance. Machine learning can be an early adjunctive diagnostic method but requires further research and validation to determine its practical efficiency and clinical application prospects.

Systematic review registration

https://www.crd.york.ac.uk/prospero/, identifier CRD42023387057.

Application of Machine Learning for Differentiating Bone Malignancy on Imaging: A Systematic Review

An accurate diagnosis of bone tumours on imaging is crucial for appropriate and successful treatment. The advent of Artificial intelligence (AI) and machine learning methods to characterize and assess bone tumours on various imaging modalities may assist in the diagnostic workflow. The purpose of this review article is to summarise the most recent evidence for AI techniques using imaging for differentiating benign from malignant lesions, the characterization of various malignant bone lesions, and their potential clinical application. A systematic search through electronic databases (PubMed, MEDLINE, Web of Science, and clinicaltrials.gov) was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 34 articles were retrieved from the databases and the key findings were compiled and summarised. A total of 34 articles reported the use of AI techniques to distinguish between benign vs. malignant bone lesions, of which 12 (35.3%) focused on radiographs, 12 (35.3%) on MRI, 5 (14.7%) on CT and 5 (14.7%) on PET/CT. The overall reported accuracy, sensitivity, and specificity of AI in distinguishing between benign vs. malignant bone lesions ranges from 0.44–0.99, 0.63–1.00, and 0.73–0.96, respectively, with AUCs of 0.73–0.96. In conclusion, the use of AI to discriminate bone lesions on imaging has achieved a relatively good performance in various imaging modalities, with high sensitivity, specificity, and accuracy for distinguishing between benign vs. malignant lesions in several cohort studies. However, further research is necessary to test the clinical performance of these algorithms before they can be facilitated and integrated into routine clinical practice.

Radiologists with assistance of deep learning can achieve overall accuracy of benign-malignant differentiation of musculoskeletal tumors comparable with that of pre-surgical biopsies in the literature

PURPOSE

The purpose of this study was to assess if radiologists assisted by deep learning (DL) algorithms can achieve diagnostic accuracy comparable to that of pre-surgical biopsies in benign-malignant differentiation of musculoskeletal tumors (MST).

METHODS

We first conducted a systematic review of literature to get the respective overall diagnostic accuracies of fine-needle aspiration biopsy (FNAB) and core needle biopsy (CNB) in differentiating between benign and malignant MST, by synthesizing data from the articles meeting our inclusion criteria. To compared against the accuracies reported in literature, we then invited 4 radiologists, respectively with 2 (A), 6 (B), 7 (C), and 33 (D) years of experience in interpreting musculoskeletal MRI to perform diagnostic tests on our own dataset (n = 62), with and without assistance of a previously developed DL algorithm. The gold standard for benign-malignant differentiation was histopathologic confirmation or clinical/radiographic follow-up.

RESULTS

For FNAB, a meta-analysis containing 4604 samples met the inclusion criteria, with the overall diagnostic accuracy reported to be 0.77. For CNB, an overall accuracy of 0.86 was derived by synthesizing results from 7 original research articles containing a total of 587 samples. On our internal MST dataset, the invited radiologists, respectively, achieved diagnostic accuracies of 0.84 (A), 0.89 (B), 0.87 (C), and 0.90 (D), with the assistance of DL.

CONCLUSION

Use of DL algorithms on musculoskeletal dynamic contrast-enhanced MRI improved the benign-malignant differentiation accuracy of radiologists to a level comparable to that of pre-surgical biopsies. The developed DL algorithms have a potential to lower the risk of miss-diagnosing malignancy in radiological practice.

Diagnosis after zooming in: A multilabel classification model by imitating doctor reading habits to diagnose brain diseases

PURPOSE

Computed tomography (CT) has the advantages of being low cost and noninvasive and is a primary diagnostic method for brain diseases. However, it is a challenge for junior radiologists to diagnose CT images accurately and comprehensively. It is necessary to build a system that can help doctors diagnose and provide an explanation of the predictions. Despite the success of deep learning algorithms in the field of medical image analysis, the task of brain disease classification still faces challenges: Researchers lack attention to complex manual labeling requirements and the incompleteness of prediction explanations. More importantly, most studies only measure the performance of the algorithm, but do not measure the effectiveness of the algorithm in the actual diagnosis of doctors.

METHODS

In this paper, we propose a model called DrCT2 that can detect brain diseases without using image-level labels and provide a more comprehensive explanation at both the slice and sequence levels. This model achieves reliable performance by imitating human expert reading habits: targeted scaling of primary images from the full slice scans and observation of suspicious lesions for diagnosis. We evaluated our model on two open-access data sets: CQ500 and the RSNA Intracranial Hemorrhage Detection Challenge. In addition, we defined three tasks to comprehensively evaluate model interpretability by measuring whether the algorithm can select key images with lesions. To verify the algorithm from the perspective of practical application, three junior radiologists were invited to participate in the experiments, comparing the effects before and after human-computer cooperation in different aspects.

RESULTS

The method achieved F1-scores of 0.9370 on CQ500 and 0.8700 on the RSNA data set. The results show that our model has good interpretability under the premise of good performance. Human radiologist evaluation experiments have proven that our model can effectively improve the accuracy of the diagnosis and improve efficiency.

CONCLUSIONS

We proposed a model that can simultaneously detect multiple brain diseases. The report generated by the model can assist doctors in avoiding missed diagnoses, and it has good clinical application value.

An update on radiomics techniques in primary liver cancers

BACKGROUND

Radiomics is a progressing field of research that deals with the extraction of quantitative metrics from medical images. Radiomic features detention indirectly tissue features such as heterogeneity and shape and can, alone or in combination with demographic, histological, genomic, or proteomic data, be used for decision support system in clinical setting.

METHODS

This article is a narrative review on Radiomics in Primary Liver Cancers. Particularly, limitations and future perspectives are discussed.

RESULTS

In oncology, assessment of tissue heterogeneity is of particular interest: genomic analysis have demonstrated that the degree of tumour heterogeneity is a prognostic determinant of survival and an obstacle to cancer control. Therefore, that Radiomics could support cancer detection, diagnosis, evaluation of prognosis and response to treatment, so as could supervise disease status in hepatocellular carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC) patients. Radiomic analysis is a convenient radiological image analysis technique used to support clinical decisions as it is able to provide prognostic and / or predictive biomarkers that allow a fast, objective and repeatable tool for disease monitoring.

CONCLUSIONS

Although several studies have shown that this analysis is very promising, there is little standardization and generalization of the results, which limits the translation of this method into the clinical context. The limitations are mainly related to the evaluation of data quality, repeatability, reproducibility, overfitting of the model.

TRIAL REGISTRATION

Not applicable.